Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers, Breast Cancer Research

Introduction Cis-acting regulatory single nucleotide polymorphisms (SNPs) at specific loci may modulate penetrance of germline mutations at the same loci by introducing different levels of expression of the wild-type allele. We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism. Methods We combined haplotype analysis and differential allelic expression of BRCA2 in breast tissue to identify expression haplotypes and candidate cis-regulatory variants. These candidate variants underwent selection based on in silico predictions for regulatory potential and disruption of transcription factor binding, and were functionally analyzed in vitro and in vivo in normal and breast cancer cell lines. SNPs tagging the expression haplotypes were correlated with the total expression of several genes in breast tissue measured by Taqman and microarray technologies. The effect of the expression haplotypes on breast cancer risk in BRCA2 mutation carriers was investigated in 2,754 carriers. Results We identified common haplotypes associated with differences in the levels of BRCA2 expression in human breast cells. We characterized three cis-regulatory SNPs located at the promoter and two intronic regulatory elements which affect the binding of the transcription factors C/EBPα, HMGA1, D-binding protein (DBP) and ZF5. We showed that the expression haplotypes also correlated with changes in the expression of other genes in normal breast. Furthermore, there was suggestive evidence that the minor allele of SNP rs4942440, which is associated with higher BRCA2 expression, is also associated with a reduced risk of breast cancer (per-allele hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.72 to 1.00, P-trend = 0.048). Conclusions Our work provides further insights into the role of cis-regulatory variation in the penetrance of disease-causing mutations. We identified small-effect genetic variants associated with allelic expression differences in BRCA2 which could possibly affect the risk in mutation carriers through altering expression levels of the wild-type allele.

PDF) Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Frontiers Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities - ScienceDirect

Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant

The sex hormone system in carriers of BRCA1/2 mutations: a case-control study - The Lancet Oncology

Frontiers Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant

Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation, Hereditary Cancer in Clinical Practice

PDF] Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Effects of BRCA2 cis-regulation in normal breast and cancer risk

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers, Breast Cancer Research

The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers - ScienceDirect

Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays, Biological Procedures Online